Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
P/B ratio for Geron Corporation (GERN)
P/B ratio as of 2023: 4.86
According to Geron Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.86. At the end of 2022 the company had a P/B ratio of 11.52.
P/B ratio history for Geron Corporation from 1996 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 4.86 |
| 2022 | 11.52 |
| 2021 | 3.16 |
| 2020 | 2.05 |
| 2019 | 1.91 |
| 2018 | 0.99 |
| 2017 | 2.76 |
| 2016 | 2.69 |
| 2015 | 5.38 |
| 2014 | 3.82 |
| 2013 | 9.59 |
| 2012 | 1.97 |
| 2011 | 1.19 |
| 2010 | 2.49 |
| 2009 | 2.68 |
| 2008 | 2.05 |
| 2007 | 1.94 |
| 2006 | 3.15 |
| 2005 | 2.47 |
| 2004 | 2.77 |
| 2003 | 2.74 |
| 2002 | 2.82 |
| 2001 | 2.95 |
| 2000 | 4.76 |
| 1999 | 7.05 |
| 1998 | 3.59 |
| 1997 | 3.90 |
| 1996 | 2.73 |